Resistant Hypertension Clinical Trial
Official title:
Effects and Safety of Sacubitril/Valsartan Versus Valsartan on Refractory Hypertension: The EOSORH Trial
Resistant hypertension (RH) accounted for a considerable proportion of patients with hypertension. It has been revealed to impose certain adverse effects on the prognosis of patients with cardiovascular diseases. The antihypertensive effect of sacubitril/valsartan being fully confirmed in previous studies, there were no related randomized controlled trials (RCT) about this potency among Chinese patients with RH. The investigators designed this study to evaluated effects and safety of sacubitril/valsartan versus valsartan on Chinese patients with RH.
Background Resistant hypertension (RH) accounted for a considerable proportion of patients with hypertension. It has been revealed to impose certain adverse effects on the prognosis of patients with cardiovascular diseases. The antihypertensive effect of sacubitril/valsartan being fully confirmed in previous studies, there were no related randomized controlled trials (RCT) about this potency among Chinese patients with RH. Purpose Describing the design of the Effects of Sacubitril/valsartan Versus Valsartan on Refractory Hypertension (EOSORH) trial. Methods and analysis This is a monocentric, randomized, parallel-group, controlled trial which will investigate the efficacy and safety of sacubitril/valsartan in the treatment of Chinese patients with RH. A total of 138 patients will be enrolled who are diagnosed with RH according to the Guidelines for Prevention and Treatment of Hypertension in China (2018 revision). After a washout period, subjects will be randomized to sacubitril/valsartan group or valsartan group in a 1:1 ratio. The primary outcome is the change in 24 hours average ambulatory systolic blood pressure (SBP) from baseline to 8 weeks after randomization, comparing the sacubitril/valsartan group with valsartan group. The secondary outcomes including change in 24 hours average ambulatory diastolic blood pressure (DBP), clinic blood pressure and series of cardiac and renal hematologic indicators. Safety endpoints will also be evaluated, covered changes in blood potassium level, renal function, hypotension, etc. Full Analysis Set (FAS), per-protocol set (PPS) and safety set (SS) will be defined. Baseline data will be analyzed by using data from FAS whereas the analysis of primary outcome will be based on FAS and PPS but the conclusions of FAS are dominant. Ethics and dissemination The research protocol has been approved by the Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. This research is designed to investigate the efficacy and safety of sacubitril/valsartan in Chinese RH patients. Findings will be shared by Sun Yat-sen Memorial Hospital, policymakers and the academic community to promote the clinical pharmacal therapy of RH in China. Discussion The effects of sacubitril/valsartan on hypertension have been widely reported by a series of large RCT in recent years, while its application in RH patients is still elusive. The study will provide a new pharmacal strategy for the treatment of RH. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04388124 -
VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION
|
Phase 2 | |
| Withdrawn |
NCT01939392 -
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06228677 -
Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
|
||
| Recruiting |
NCT04213963 -
Prospective Study on Primary Aldosteronism in Resistant Hypertension
|
||
| Recruiting |
NCT05563077 -
Aerobic Exercise and Resistant Hypertension
|
N/A | |
| Recruiting |
NCT03758196 -
Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension（RSDARH）
|
N/A | |
| Active, not recruiting |
NCT03179800 -
CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™
|
N/A | |
| Completed |
NCT04519658 -
A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
|
Phase 2 | |
| Not yet recruiting |
NCT05552300 -
Superselective Adrenal Arterial Embolization for Resistant Hypertension
|
N/A | |
| Not yet recruiting |
NCT05426707 -
Remote Ischemic Conditioning for the Treatment of Resistant Hypertension
|
N/A | |
| Completed |
NCT04345198 -
Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension
|
N/A | |
| Active, not recruiting |
NCT05562934 -
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
|
Phase 2 | |
| Recruiting |
NCT06034743 -
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
|
Phase 3 | |
| Withdrawn |
NCT02926495 -
Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.
|
N/A | |
| Active, not recruiting |
NCT02670681 -
Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects
|
N/A | |
| Completed |
NCT02572024 -
The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study)
|
N/A | |
| Terminated |
NCT02295683 -
Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
|
||
| Completed |
NCT02001350 -
Carotid Ultrasound Study
|
N/A | |
| Recruiting |
NCT04331691 -
Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension
|
Phase 4 | |
| Recruiting |
NCT04637152 -
Sacubitril/Valsartan in Resistant Hypertension
|
Phase 2 |